---
title: "OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293213635.md"
description: "OKYO Pharma filed its 2026 Annual Report (Form 20-F), reporting $25 million in raised capital and a strengthened balance sheet with $20.6 million in cash. This funding supports the upcoming Phase 3 NEPTUNE trial for urcosimod, targeting neuropathic corneal pain. While analysts maintain a 'Buy' rating with a $5 target, TipRanks' AI tool rates the stock 'Neutral' due to weak financial fundamentals despite improved cost control."
datetime: "2026-07-20T11:57:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293213635.md)
  - [en](https://longbridge.com/en/news/293213635.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293213635.md)
generator: "portal-rs"
---

# OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial

The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( (OKYO) ).

On July 20, 2026, OKYO Pharma filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026 with the U.S. Securities and Exchange Commission, accompanied by a corporate update highlighting stronger finances and advancing clinical programs. During the year, the company raised about $25 million, including a February 2026 public offering that generated roughly $22 million in gross proceeds, leaving cash and equivalents of $20.6 million at fiscal year-end.

This reinforced balance sheet is expected to fund OKYO through completion of its FDA-agreed global NEPTUNE Phase 3 pivotal trial of urcosimod in neuropathic corneal pain. The trial, planned to start in the second half of 2026, will enroll around 111 patients in the U.S. and Europe in a single-dose regimen, and has been designed as a potential registrational study, underscoring the company’s strengthened position as it targets key clinical and regulatory milestones for its lead asset.

The most recent analyst rating on (OKYO) stock is a Buy  
 with a $5.00 price target.  
 To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock,  
 see the OKYO Stock Forecast page. 

**Spark’s Take on OKYO Stock**

According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.

The score is primarily held down by weak financial fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Improved 2025 cost control and a debt-free balance sheet provide only limited offset.

To see Spark’s full report on OKYO stock,  
 click here. 

**More about OKYO Pharma Limited Sponsored ADR**

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and anterior segment eye diseases. Listed on the Nasdaq Capital Market, the company’s lead product candidate is urcosimod, a first-in-class chemerin peptide agonist targeting ocular immune and neuronal pathways to address significant unmet needs in neuropathic corneal pain.

**Average Trading Volume:** 81,296

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $73.46M

For a thorough assessment of OKYO stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [OKYO.US](https://longbridge.com/en/quote/OKYO.US.md)

## Related News & Research

- [OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial](https://longbridge.com/en/news/293646761.md)
- [OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial](https://longbridge.com/en/news/293487942.md)
- [Dogwood Therapeutics to host virtual KOL event on Halneuron for chemotherapy-induced neuropathic pain](https://longbridge.com/en/news/296106790.md)
- [Gaush Neotech signs five-year exclusive global distribution deal with Heidelberg for T3 corneal confocal microscopy outside China](https://longbridge.com/en/news/296103795.md)
- [OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial](https://longbridge.com/en/news/293350393.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**